Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Patient-centered decision making about hot flash treatments often incorporates a balance of efficacy and side effects in addition to patient preference. This systematic review examines randomized controlled trials (RCTs) comparing at least two non-hormonal hot flash treatments in breast cancer survivors. In July 2015, PubMed, SCOPUS, CINAHL, Cochrane, and Web of Science databases were searched for RCTs comparing active, non-hormonal hot flash treatments in female breast cancer survivors. Thirteen trials were included after identifying 906 potential studies. Four trials were dose comparison studies of pharmacologic treatments citalopram, venlafaxine, gabapentin, and paroxetine. Hot flash reduction did not differ by tamoxifen or aromatase inhibitor use. Citalopram 10, 20, and 30 mg daily had comparable outcomes. Venlafaxine 75 mg daily improved hot flashes without additional side effects from higher dosing. Gabapentin 900 mg daily improved hot flashes more than 300 mg. Paroxetine 10 mg daily had fewer side effects than 20 mg. Among four trials comparing different pharmacologic treatments, venlafaxine alleviated hot flash symptoms faster than clonidine; participants preferred venlafaxine over gabapentin. Five trials compared pharmacologic to non-pharmacologic treatments. Acupuncture had similar efficacy to venlafaxine and gabapentin but may have longer durability after completing treatment and fewer side effects. We could not perform a pooled meta-analysis because outcomes were not reported in comparable formats. Clinical trial data on non-hormonal hot flash treatments provide comparisons of hot flash efficacy and other patient important outcomes to guide clinical management. Clinicians can use the information to help patients select hot flash interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine.118, 119, 120, 121”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“This systematic review was conducted in accordance with PRISMA guidelines [30].”
MethodThe CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234 · cited 2×
“Additional effects (Pittsburgh Sleep Quality Index [57], Menopausal Rating Scale [58])”
BackgroundInfluentialThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
A self-rating depression scale
ZUNG, W. W. K. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01720310065008 · Cited by 9,813
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 3×
“, risk of bias); consistency of effect; imprecision; indirectness; and publication bias [32].”
BackgroundMethodInfluentialAssessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory
Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., & Engstrom, M. C. (2000) · Cancer · doi:10.1002/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v · Cited by 1,360
Short Form of the Profile of Mood States (POMS-SF): Psychometric information.
Curran, S. L., Andrykowski, M. A., & Studts, J. L. (1995) · Psychological Assessment · doi:10.1037//1040-3590.7.1.80 · Cited by 808
A menopause-specific quality of life questionnaire: development and psychometric properties
Hilditch, J. R., Lewis, J., Peter, A., van Maris, B., Ross, A., Franssen, E., Guyatt, G. H., Norton, P. G., & Dunn, E. (1996) · Maturitas · doi:10.1016/s0378-5122(96)82006-8 · Cited by 750 · cited 1×
“Quality of life (MenQOL [59], SF-12 [60]) 420 Breast Cancer Res Treat (2016) 156:415–426”
BackgroundLoprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737 · cited 5×
“Four randomized controlled trials tested different doses of prescription pharmacologic treatments on hot flashes (Table 1, Supplementary material 2) [12, 14, 16, 17].”
BackgroundResultInfluentialThe Menopause Rating Scale (MRS) scale: A methodological review
Heinemann, K., Ruebig, A., Potthoff, P., Schneider, H. P., Strelow, F., Heinemann, L. A., & Thai, D. M. (2004) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-2-45 · Cited by 618
Methodologic lessons learned from hot flash studies.
Sloan, J. A., Loprinzi, C. L., Novotny, P. J., Barton, D. L., Lavasseur, B. I., & Windschitl, H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4280 · Cited by 462 · cited 1×
“In addition, despite fairly consistent collection of hot flash frequency and score data using hot flash diaries [44], studies did not consistently report outcomes in comparable formats, which prohibited pooling estimates in a meta-analysis.”
BackgroundDay, R., Ganz, P. A., Costantino, J. P., Cronin, W. M., Wickerham, D. L., & Fisher, B. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2659 · Cited by 438 · cited 1×
“Hot flashes are symptoms of estrogen deprivation that are exacerbated by anti-estrogen therapy used for breast cancer treatment [2, 3].”
BackgroundIncreased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer Survivors
Holmberg, L., Iversen, O.-E., Rudenstam, C. M., Hammar, M., Kumpulainen, E., Jaskiewicz, J., Jassem, J., Dobaczewska, D., Fjosne, H. E., Peralta, O., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn058 · Cited by 344 · cited 1×
“While menopausal hormone therapy can reduce hot flashes by up to 90 % [9], concerns that systemic estrogen exposure increases cancer recurrence rates in breast cancer survivors limit its use [10, 11].”
BackgroundPandya, K. J., Morrow, G. R., Roscoe, J. A., Zhao, H., Hickok, J. T., Pajon, E., Sweeney, T. J., Banerjee, T. K., & Flynn, P. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67215-7 · Cited by 333 · cited 4×
“[16] 420 participants with breast cancer”
BackgroundInfluentialBarnabei, V. M., Cochrane, B. B., Aragaki, A. K., Nygaard, I., Williams, R. S., McGovern, P. G., Young, R. L., Wells, E. C., OʼSullivan, M. J., Chen, B., et al. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000158120.47542.18 · Cited by 320 · cited 1×
“While menopausal hormone therapy can reduce hot flashes by up to 90 % [9], concerns that systemic estrogen exposure increases cancer recurrence rates in breast cancer survivors limit its use [10, 11].”
BackgroundCouzi, R. J., Helzlsouer, K. J., & Fetting, J. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2737 · Cited by 315 · cited 1×
“Hot flashes are highly prevalent and persistent among breast cancer survivors [1].”
BackgroundThe Sexual Activity Questionnaire: A measure of women's sexual functioning
Thirlaway, K., Fallowfield, L., & Cuzick, J. (1996) · Quality of Life Research · doi:10.1007/bf00435972 · Cited by 309 · cited 3×
“Compared to vitamin E, gabapentin 900 mg daily significantly improved hot flashes (mean 63 % reduction in Table 1 Summary of Studies Reference Participants Interventions Outcome measures Dose comparisons of pharmacologic treatments Barton et al. [12] 254 participants (87 breast cancer survivors) Postmenopausal [14 hot…”
BackgroundInfluentialTransdermal clonidine for ameliorating tamoxifen-induced hot flashes.
Goldberg, R. M., Loprinzi, C. L., O'Fallon, J. R., Veeder, M. H., Miser, A. W., Mailliard, J. A., Michalak, J. C., Dose, A. M., Rowland, K. M., & Burnham, N. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.155 · Cited by 292
Menopausal Hormone Therapy After Breast Cancer: The Stockholm Randomized Trial
von Schoultz, E., Rutqvist, L. E., & on Behalf of the Stockholm Breast Cancer Study Group (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji071 · Cited by 250 · cited 1×
“While menopausal hormone therapy can reduce hot flashes by up to 90 % [9], concerns that systemic estrogen exposure increases cancer recurrence rates in breast cancer survivors limit its use [10, 11].”
BackgroundElkins, G., Marcus, J., Stearns, V., Perfect, M., Rajab, M. H., Ruud, C., Palamara, L., & Keith, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6389 · Cited by 245
Carson, J. W., Carson, K. M., Porter, L. S., Keefe, F. J., & Seewaldt, V. L. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0587-5 · Cited by 231
Walker, E. M., Rodriguez, A. I., Kohn, B., Ball, R. M., Pegg, J., Pocock, J. R., Nunez, R., Peterson, E., Jakary, S., & Levine, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5150 · Cited by 228 · cited 6×
“Acupuncture was compared with gabapentin or venlafaxine in two trials [25, 40].”
BackgroundMethodInfluentialStearns, V., Slack, R., Greep, N., Henry-Tilman, R., Osborne, M., Bunnell, C., Ullmer, L., Gallagher, A., Cullen, J., Gehan, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.081 · Cited by 224 · cited 7×
“Four randomized controlled trials tested different doses of prescription pharmacologic treatments on hot flashes (Table 1, Supplementary material 2) [12, 14, 16, 17].”
BackgroundMethodResultInfluentialGupta, P., Sturdee, D. W., Palin, S. L., Majumder, K., Fear, R., Marshall, T., & Paterson, I. (2006) · Climacteric · doi:10.1080/13697130500487224 · Cited by 217
Deng, G., Vickers, A. J., Yeung, K. S., D'Andrea, G. M., Xiao, H., Heerdt, A. S., Sugarman, S., Troso-Sandoval, T., Seidman, A. D., Hudis, C. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0774 · Cited by 190
Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis
Loprinzi, C. L., Sloan, J., Stearns, V., Slack, R., Iyengar, M., Diekmann, B., Kimmick, G., Lovato, J., Gordon, P., Pandya, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6253 · Cited by 179
Acupuncture for menopausal hot flushes
Dodin, S., Blanchet, C., Marc, I., Ernst, E., Wu, T., Vaillancourt, C., Paquette, J., & Maunsell, E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007410.pub2 · Cited by 178
Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C., Pinotti, G., Spazzapan, S., Ruhstaller, T., Puglisi, F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00049-2 · Cited by 178 · cited 1×
“Hot flashes are symptoms of estrogen deprivation that are exacerbated by anti-estrogen therapy used for breast cancer treatment [2, 3].”
BackgroundLoprinzi, C. L., Qin, R., Baclueva, E. P., Flynn, K. A., Rowland, K. M., Graham, D. L., Erwin, N. K., Dakhil, S. R., Jurgens, D. J., & Burger, K. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5647 · Cited by 165
Non-hormonal interventions for hot flushes in women with a history of breast cancer
Rada, G., Capurro, D., Pantoja, T., Corbalán, J., Moreno, G., Letelier, L. M., & Vera, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004923.pub2 · Cited by 160
Hervik, J. B., & Mjåland, O. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0210-3 · Cited by 134
Impact of Hot Flashes on Quality of Life Among Postmenopausal Women Being Treated for Breast Cancer
Stein, K., Jacobsen, P. B., Hann, D. M., Greenberg, H., & Lyman, G. H. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00142-1 · Cited by 132
Barton, D. L., LaVasseur, B. I., Sloan, J. A., Stawis, A. N., Flynn, K. A., Dyar, M., Johnson, D. B., Atherton, P. J., Diekmann, B., & Loprinzi, C. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6379 · Cited by 132 · cited 6×
“Four randomized controlled trials tested different doses of prescription pharmacologic treatments on hot flashes (Table 1, Supplementary material 2) [12, 14, 16, 17].”
BackgroundResultInfluentialInteractions Between Tamoxifen and Antidepressants via Cytochrome P450 2D6
Desmarais, J. E., & Looper, K. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04856blu · Cited by 131 · cited 1×
“Paroxetine has been shown to have a strong interaction, while venlafaxine and gabapentin are not known to have an interaction with tamoxifen [42].”
BackgroundBordeleau, L., Pritchard, K. I., Loprinzi, C. L., Ennis, M., Jugovic, O., Warr, D., Haq, R., & Goodwin, P. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9230 · Cited by 130 · cited 3×
“[34] 66 participants with breast cancer”
BackgroundInfluentialMao, J. J., Bowman, M. A., Xie, S. X., Bruner, D., DeMichele, A., & Farrar, J. T. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9412 · Cited by 126 · cited 6×
“Acupuncture was compared with gabapentin or venlafaxine in two trials [25, 40].”
BackgroundMethodInfluentialSelf-citationLoibl, S., Schwedler, K., von Minckwitz, G., Strohmeier, R., Mehta, K., & Kaufmann, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl478 · Cited by 118 · cited 3×
“15 mg daily in decreasing hot flash frequency and score in one study [36]; the other two studies showed no difference [33, 35].”
BackgroundResultBoekhout, A. H., Vincent, A. D., Dalesio, O. B., van den Bosch, J., Foekema-Töns, J. H., Adriaansz, S., Sprangers, S., Nuijen, B., Beijnen, J. H., & Schellens, J. H. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1298 · Cited by 116 · cited 2×
“15 mg daily in decreasing hot flash frequency and score in one study [36]; the other two studies showed no difference [33, 35].”
ResultBuijs, C., Mom, C. H., Willemse, P. H. B., Boezen, H. M., Maurer, J. M., Wymenga, A. N. M., de Jong, R. S., Nieboer, P., de Vries, E. G. E., & Mourits, M. J. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0138-7 · Cited by 98 · cited 2×
“15 mg daily in decreasing hot flash frequency and score in one study [36]; the other two studies showed no difference [33, 35].”
ResultBokmand, S., & Flyger, H. (2012) · The Breast · doi:10.1016/j.breast.2012.07.015 · Cited by 97
Menopausal-type symptoms in young breast cancer survivors
Leining, M. G., Gelber, S. I., Rosenberg, R., Przypyszny, M., Winer, E. P., & Partridge, A. H. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl299 · Cited by 96 · cited 1×
“Furthermore, for pre-menopausal breast cancer patients, chemotherapy abruptly disrupts or permanently ceases ovarian function, leading to the onset of debilitating hot flashes [4, 5].”
BackgroundMarino, J. L., Saunders, C. M., Emery, L. I., Green, H., Doherty, D. A., & Hickey, M. (2014) · Menopause · doi:10.1097/gme.0b013e3182976f46 · Cited by 86
Bao, T., Cai, L., Snyder, C. F., Betts, K. J., Tarpinian, K., Gould, J., Jeter, S. C., Medeiros, M., Chumsri, S., Bardia, A., et al. (2013) · Cancer · doi:10.1002/cncr.28352 · Cited by 76
Practice Bulletin No. 126: Management of Gynecologic Issues in Women With Breast Cancer
(2012) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31824e12ce · Cited by 69
Liljegren, A., Gunnarsson, P., Landgren, B.-M., Robéus, N., Johansson, H., & Rotstein, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1283-3 · Cited by 65
Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E
Biglia, N., Sgandurra, P., Peano, E., Marenco, D., Moggio, G., Bounous, V., Tomasi Cont, N., Ponzone, R., & Sismondi, P. (2009) · Climacteric · doi:10.1080/13697130902736921 · Cited by 56
(CEPO), C. D. L. D. P. E. O., L’Espérance, S., Frenette, S., Dionne, A. R., & Dionne, J.-Y. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1732-8 · Cited by 52
The EuroQol Group after 25 years
Brooks, R. G. (2012) · Springer eBooks · doi:10.1007/978-94-007-5158-3 · Cited by 46
Bardia, A., Novotny, P., Sloan, J., Barton, D., & Loprinzi, C. (2009) · Menopause · doi:10.1097/gme.0b013e31818c91ca · Cited by 40
MacLaughlan David, S., Salzillo, S., Bowe, P., Scuncio, S., Malit, B., Raker, C., Gass, J. S., Granai, C. O., & Dizon, D. S. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003138 · Cited by 37 · cited 5×
“[38] Gabapentin 900 mg daily or hypnotic inductions (weekly for 3 weeks) $ N/A N/A $”
BackgroundMethodResultInfluentialYoo, C., Yun, M. R., Ahn, J. H., Jung, K. H., Kim, H. J., Kim, J. E., Park, J. Y., Park, K. O., Yoon, D. H., & Kim, S. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2227-5 · Cited by 36 · cited 1×
“Furthermore, for pre-menopausal breast cancer patients, chemotherapy abruptly disrupts or permanently ceases ovarian function, leading to the onset of debilitating hot flashes [4, 5].”
BackgroundOthman, A. H., & Zaky, A. H. (2014) · Pain Medicine · doi:10.1111/pme.12331 · Cited by 33 · cited 4×
“Pregabalin was compared with stellate ganglion block in one study [39].”
BackgroundMethodInfluentialAbstracts of the 2011 International MASCC/ISOO Symposium
Mayo, B., Bowen, J., Stringer, A., Bateman, E., Plews, E., Darby, J., Boyle, F. M., & Keefe, D. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1184-y · Cited by 9
Research works printed but not linked: 2
- Stewart AL, Ware JE (1992) Measuring Function and Well Being: The Medical Outcomes Study Approach. Duke University Press, Durham
- Meijman TF, de Vries-Griever AH, de Vries G (1988) The evaluation of the Groningen sleep quality scale. Heymans Bulletin (HB 88-13-EX), Groningen
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine.(118-121) Sleep disturbances may be treated with melatonin.”
BackgroundSurvivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Denlinger, C. S., Sanft, T., Baker, K. S., Baxi, S., Broderick, G., Demark-Wahnefried, W., Friedman, D. L., Goldman, M., Hudson, M., Khakpour, N., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0146 · Cited by 152
Zia, F. Z., Olaku, O. O., Bao, T., Berger, A. M., Deng, G., Fan, A. Y., Garcia, M. K., Herman, P. M., Kaptchuk, T. J., Ladas, E. J., et al. (2017) · JNCI Monographs · doi:10.1093/jncimonographs/lgx005 · Cited by 143
“Non–hormonally based drugs such as venlafaxine, gabapentin, citalopram, and clonidine have shown benefit, but have also shown considerable side effects (40).”
BackgroundSelf-citation
Metadata
- Authors
- Johns, C., Seav, S. M., Dominick, S. A., Gorman, J. R., Li, H., Natarajan, L., Mao, J. J., & Irene Su, H.
- Affiliations
- University of California, San Francisco (US)
- University of California San Diego (US)
- Oregon State University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Breast Cancer Research and Treatment
- Published
- 2016-03-26
- Volume
- 156
- Issue
- 3
- Pages
- 415-426
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC4838539
- OpenAlex
- W2310666724
- Cited by
- 72
- References
- 63
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 5 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 10 · 2017: 7 · 2016: 7
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- California Breast Cancer Research Program (200B-0 144)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- hot flashes, breast cancer survivors, venlafaxine, gabapentin, paroxetine, citalopram, clonidine, acupuncture, aromatase inhibitors, tamoxifen, patient-centered decision-making, dose comparison, adverse effects
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Breast Neoplasms, Female, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Survivors, Evidence-Based Medicine, Disease Management, Hot Flashes, Patient Preference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.